Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Study reveals the various ways patients with multiple sclerosis acquire disability

A new study conducted by researchers from the Corrine Goldsmith Dickinson Center for Multiple Sclerosis at Icahn School of Medicine at Mount Sinai in collaboration with Novartis, the University of Oxford and key MS experts across the globe, has revealed detailed information on the various ways patients with multiple sclerosis (MS) acquire disability.

23 Feb 2022

Genetics may influence how the body responds to vaccines and boosters

Genetics play an important role in how our bodies respond to vaccines and booster shots, suggesting that certain protective responses elicited by vaccination could be more effective with personalization, according to a new study led by University of Michigan researchers.

23 Feb 2022

Understanding the immune responses after secondary vaccinations with Pfizer and Moderna vaccines

In a new study, researchers assessed the serological responses to secondary booster doses of Pfizer's Comirnaty and Moderna's Spikevax COVID-19 vaccines.

23 Feb 2022

Study explores the impact of COVID-19 on pancreatic cells

New study findings showed that SARS-CoV-2 caused a productive yet restricted infection of pancreatic islet cells and an insignificant inflammatory response.

23 Feb 2022

Why is it Important to Democratize Proteomics Data?

In this interview, we speak to Steve Kosteski from IsoPlexis about the importance of single-cell proteomics within the life sciences sector.

From Society for Laboratory Automation and Screening (SLAS) 23 Feb 2022

SARS-Cov-2 reinfection in Syrian hamsters does not result in disease

Researchers have been investigating the reinfection of different SARS-CoV-2 variants in Syrian hamsters and found that this does not seem to result in disease or any significant pulmonary pathology.

23 Feb 2022

Omicron neutralizing titers after third BNT162b2 dose are persistent

The new study, published in the journal Cell Host and Microbe, also finds that the neutralization against Omicron remains robust at four months after the third dose of the BNT162b2 vaccine.

22 Feb 2022

Study shows Pfizer-BioNTech booster protects over 65s against Delta and Omicron

New research in nursing home residents found that a third dose of the Pfizer-BioNTech COVID-19 vaccine was effective for at least three months in protecting against the Delta and Omicron variant. While two doses of an mRNA COVID-19 vaccine showed poor neutralization to Omicron than Delta, a booster shot increased neutralizing antibody responses.

22 Feb 2022

Pre-existing B-cell immunity against SARS-CoV-2 not detected in pre-pandemic samples

A recent study investigates samples solated from unexposed individuals pre-pandemic to determine the presence of pre-existing SARS-CoV-2 B-cell immunity.

22 Feb 2022

Role of SARS-CoV-2 seroprevalence studies in disease surveillance

A new study aimed to determine the timelessness of SARS-CoV-2 seroprevalence studies in providing information that is useful in public health surveillance.

22 Feb 2022

Exploring the potential of mosaic RBD nanoparticles to fight SARS-CoV-2

Researchers explore the potential of mosaic receptor-binding domain nanoparticles in protective immunity against SARS-CoV-2

22 Feb 2022

New approach for extensive screening of monoclonal antibody clones against multiple myeloma cells

Multiple myeloma (MM) is a largely incurable cancer of plasma cells with an extremely poor prognosis. However, investigators from Japan have recently found that a common component of amino acid transporters, CD98 heavy chain, represents an effective monoclonal antibody target in treating MM.

22 Feb 2022

Study explores the decline in viral load and immune response in COVID-19 patients

Researchers described the changes in viral ribonucleic acid the decline in viral load, and the immune response of SARS-CoV-2-infected patients, in a new preprint study.

22 Feb 2022

REGEN-COV antibody combination to prevent COVID-19 severity

A new study assessed the effectiveness of REGEN-COV, a combination of casirivimab and imdevimab monoclonal antibodies, in the prevention of COVID-19 disease severity.

22 Feb 2022

Study provides a potent biparatopic antibody against all SARS-CoV-2 variants of concern

Researchers demonstrated the potent neutralization of SARS-CoV-2 VOCs, including Omicron by the biparatopic human heavy chain variable domain.

22 Feb 2022

Study suggests anti-SARS-CoV-2 antibodies may persist lifelong post-infection

Researchers attempted to delineate the duration and stability of anti-SARS-CoV-2 antibodies in patients who had recovered from the COVID-19 infection.

22 Feb 2022

Spectrum of autoantibodies linked to autoimmune diseases in patients with different COVID-19 clinical outcomes

A broad evaluation of autoimmune disease-associated autoantibodies that have been observed in COVID-19 patients was performed.

22 Feb 2022

Time-based sensitivity of COVID-19 serological testing

In a recent study under consideration at Scientific Reports and posted to the Research Square* preprint server, researchers evaluated the impact of time on the sensitivity of four severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological assays using samples from the coronavirus disease 2019 (COVID-19) staff testing of antibody responses study(Co-Stars) in the United Kingdom (UK).

22 Feb 2022

Using IgG antibody assay to Identify natural SARS-CoV-2 infection in vaccinees

A recent study published in the journal of Mayo Clinic Proceedings predicted the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) natural infection in vaccinated individuals.

21 Feb 2022

Mathematical model suggests a clue as to when COVID-19 pandemic will turn into an endemic

A mathematical model demonstrated that high transmission rates among highly vaccinated populations of COVID-19 ultimately reduce the numbers of severe cases. This model suggests a clue as to when this pandemic will turn into an endemic.

21 Feb 2022